Novartis AG revised earnings guidance for the year 2024. For the year, net sales now expected to grow high single to low double-digit compared to the previous guidance of from mid-single-digit and core operating income now expected to grow low double-digit to mid-teens compared to the previous guidance of from high single-digit.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.97 CHF | -1.01% | -1.71% | +3.65% |
May. 02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.65% | 199B | |
+27.00% | 681B | |
+21.85% | 556B | |
-5.02% | 361B | |
+16.96% | 325B | |
+5.27% | 285B | |
+13.68% | 235B | |
-11.12% | 189B | |
-4.19% | 157B | |
+8.85% | 149B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis AG Revise Earnings Guidance for the Year 2024